Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Rhea-AI Summary
Plus Therapeutics (Nasdaq:PSTV) subsidiary CNSide Diagnostics signed a national agreement with Elevance Health, effective May 1, 2026, adding coverage for about 45.4 million people and raising total CNSide® CSF TCE assay contracted coverage to 126 million.
The CNSide® platform supports diagnosis and management of leptomeningeal metastases, with over 11,000 tests run at more than 120 U.S. cancer institutions since 2020. Reported performance includes 92% sensitivity, 95% specificity, and influence on treatment decisions in 90% of cases, supported by 9 peer-reviewed publications and the FORESEE clinical trial.
AI-generated analysis. Not financial advice.
Positive
- National Elevance Health agreement adds coverage for about 45.4 million people
- Total CNSide CSF TCE assay contracted coverage reaches 126 million people
- Over 11,000 CNSide tests performed at more than 120 U.S. cancer institutions
- Reported 92% sensitivity and 95% specificity for CNSide CSF assay
- Reported influence on treatment decisions in 90% of CNSide-tested cases
- Test available exclusively through CNSide Diagnostics as a U.S. service
Negative
- None.
News Market Reaction – PSTV
On the day this news was published, PSTV gained 7.58%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.6% during that session. Argus tracked a trough of -22.1% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $27.26M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
PSTV was down 2.94% while close biotech peers were mixed: BCAB and VRCA were up and another peer was down, indicating a stock-specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-06-23 | business update call | Positive | +2.5% | Announcement of upcoming business update call covering CNSide and Reyobiq plans. |
| 2026-06-04 | lab accreditation | Positive | +6.0% | CAP accreditation for CNSide Diagnostics clinical lab supporting U.S. commercialization. |
| 2026-05-26 | health economics data | Positive | +0.1% | New data suggesting CNSide-enabled care can substantially reduce LM-related costs. |
| 2026-05-19 | AI partnership | Positive | +1.0% | Strategic AI platform partnership to integrate CNS oncology data and workflows. |
| 2026-05-15 | Q1 2026 earnings | Positive | +11.2% | Q1 results plus milestones in REYOBIQ program and CNSide commercial rollout. |
PSTV has generally traded higher following recent positive business and CNSide-related news.
Regulatory & Risk Context
Reported short interest indicates moderately elevated positioning, which can contribute to increased share-price volatility and the potential for sharper moves when material news is released.
An effective S-3 shelf registration dated 2026-06-05 gives Plus Therapeutics flexibility to issue registered securities over several years as needed.
Market Pulse Summary
The stock moved +7.6% in the session following this news. A strong positive reaction aligns with PSTV’s recent pattern of favorable responses to CNSide milestones. Expanded coverage to 126 million lives and strong assay performance data support the commercial story, though an effective shelf registration adds ongoing financing and dilution risk.
Key Terms
cerebrospinal fluid medical
tumor cell enumeration medical
leptomeningeal metastases medical
specificity medical
AI-generated analysis. Not financial advice.
HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to 126 million people.
The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 9 peer-reviewed publications, the FORESEE clinical trial, and has been validated in the market through real-world use.
More than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, delivering high sensitivity (
This test is available exclusively through CNSide Diagnostics, LLC. as a testing service provided to health care professionals in the U.S.
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://www.plustherapeutics.com.
About Elevance Health
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 105 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.
Investor Contact
CORE IR
investor@plustherapeutics.com
